摘要
为了进一步确定黄芪、干扰素对防治感冒的效果，用人α2b型基因工程干扰素和黄芪组成复方干扰素合剂，以14、39型鼻病毒为模型，在不同人二倍体细胞培养上研究复方干扰素合剂的抗鼻病毒作用。结果表明，0.3％的黄菌注射液对人α2b型基因工程干扰素抗14型和39型鼻病毒确有协同作用，可以提高干扰素抗鼻病毒感染的能力达1．5倍左右。经与VSV病毒对比试验，证明鼻病毒对人α2b型基因工程干扰素的抗病毒作用是很敏感的。复方干扰素合剂在4、22和37℃存放18个月后．抗病毒滴度未见明显下降。如采用10万单位干扰素与黄芪组成合剂，可以产生25万单位干扰素治疗感冒的效果，这与志愿者攻击试验的所用剂量相当。
In this paper, a compound IFN mixture consisting of recombinant IFN-α 2band Astragalus membranaceus (AM) was developed for the treatment and prevention ofcommon cold. The result of an in vitro study showed that 0. 3% AM had a synergism withIFN to inhibit chronic pulmonary emphysema (CPE) caused by rhinovirus type 14 and 39 cultured in WI-38, MRC-5 and 2BC human diploid cell cultures. The antiviral activity of thecompound IFN mixture was 2. 5 times as high as that of IFN alone under above mentionedcondition. The mixture was stable to temperature. No significant decrease of the stability ofit were found after being stored at 4, 22 and 37℃ for 18 months. The possibility to developa new biotech drug (IFN mixture) for the treatment and /or prevention of common cold wasdiscussed.
出处
《中国生物制品学杂志》
CAS
CSCD
1998年第1期10-13,共4页
Chinese Journal of Biologicals
基金
国家八六三计划生物技术领域支持项目
